GIT1 Monoclonal / DyLight 350 / S39B-8
Product Details
| Description | Detects approx 90kDa. Does not cross-react with GIT2. | |
|---|---|---|
| Conjugate | DyLight 350 | |
| Clone | S39B-8 | |
| Target Species | Human, Mouse, Rat | |
| Applications | ICC, IF, WB, IHC | |
| Supplier | Novus Biologicals | |
| Catalog # | Sign in to view product details, citations, and spectra | |
| Size | ||
| Price | ||
| Antigen | ||
| Host | ||
| Isotype |
About GIT1
Enables gamma-tubulin binding activity. Involved in positive regulation of microtubule nucleation and regulation of cytokinesis. Located in several cellular components, including focal adhesion; microtubule cytoskeleton; and mitochondrion. Implicated in attention deficit hyperactivity disorder. Biomarker of Huntington's disease. [provided by Alliance of Genome Resources, Apr 2022]
Enables gamma-tubulin binding activity. Involved in positive regulation of microtubule nucleation and regulation of cytokinesis. Located in several cellular components, including focal adhesion; microtubule cytoskeleton; and mitochondrion. Implicated in attention deficit hyperactivity disorder. Biomarker of Huntington's disease. [provided by Alliance of Genome Resources, Apr 2022]
About DyLight 350
DyLight™ 350 has an excitation peak of 353 nm and an emission peak of 432 nm. It is spectrally similar to Alexa Fluor™ 350, iFluor® 350, AMCA, and Thioflavin T. DyLight™ 350 is most commonly used in flow cytometery and fluorescence microscopy applications.
DyLight™ 350 has an excitation peak of 353 nm and an emission peak of 432 nm. It is spectrally similar to Alexa Fluor™ 350, iFluor® 350, AMCA, and Thioflavin T. DyLight™ 350 is most commonly used in flow cytometery and fluorescence microscopy applications.
Experiment Design Tools
Panel Builders
Looking to design a Microscopy or Flow Cytometry experiment?
Validation References
| Additional Sources |
|
|---|
Reviews & Ratings
| Reviews |
|---|
Looking for more options?
262 GIT1 antibodies from over 23 suppliers available with over 46 conjugates.
